Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

EU approval of Russia's Sputnik V vaccine delayed, sources say

Published 06/16/2021, 04:52 AM
Updated 06/16/2021, 11:17 AM
© Reuters. FILE PHOTO: Doses of the Sputnik V vaccine against the coronavirus disease (COVID-19) are seen at a vaccination centre in Zilina, Slovakia June 7, 2021. REUTERS/Radovan Stoklasa/File Photo

By Andreas Rinke and Emilio Parodi

BERLIN (Reuters) - European Union approval of Russia's Sputnik V coronavirus vaccine will be delayed because a June 10 deadline to submit data was missed, two people familiar with the matter told Reuters, diminishing the shot's prospects in the EU's pandemic response.

One of the sources, a German government official, said the failure to provide the necessary clinical trial data to the EU medicines watchdog would postpone any go-ahead in the bloc until at least September.

"Approval of Sputnik will be delayed probably until September, maybe until the end of the year," the official said, speaking on condition of anonymity.

The European Medicines Agency (EMA) had previously been expected to conclude its review of the Russian vaccine and issue a decision in May or June.

A second source said the June 10 cut-off date not been met and that the vaccine's developer, Russia's Gamaleya Institute, said it will file the requested data next week or at the latest at the end of the month.

The Russian Direct Investment Fund (RDIF), which markets the vaccine, said the EMA review was on track.

"All of the information on the Sputnik V vaccine clinical trials has been provided and GCP (General Clinical Practice) review has been completed with positive feedback from the European Medicines Agency," the RDIF said.

"While it is up to EMA to decide on the timing of the approval procedure, the Sputnik V team expects the vaccine approval with the next two months," it added.EMA was not immediately available for comment.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

German Chancellor Angela Merkel's government has held talks to buy Sputnik V but has made any purchase contingent on EMA approval.

Frustrated by a sluggish immunisation campaign, some regional German states including Bavaria earlier this year flagged interest in placing orders for Sputnik V, but vaccination has since picked up speed.

Slovakia became the EU's second country after Hungary to start inoculating people with Sputnik V this month, despite lack of EU approval.

(Reporting Andrease Rinke in Berlin, Emilio Parodi in Milan; Additional reporting by Polina Ivanova in Moscow; Writing by Ludwig Burger and Joseph Nasr; Editing by Giles Elgood and Steve Orlofsky)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.